bio-key international - BKYI

BKYI

Close Chg Chg %
0.60 -0.03 -5.13%

Closed Market

0.57

-0.03 (5.13%)

Volume: 119.73K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Company Overview: bio-key international - BKYI

BKYI Key Data

Open

$0.61

Day Range

0.55 - 0.61

52 Week Range

0.51 - 3.68

Market Cap

$6.61M

Shares Outstanding

10.84M

Public Float

9.60M

Beta

0.37

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.02

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

210.24K

 

BKYI Performance

1 Week
 
-2.83%
 
1 Month
 
-17.55%
 
3 Months
 
-19.31%
 
1 Year
 
-61.80%
 
5 Years
 
-99.16%
 

BKYI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About bio-key international - BKYI

BIO-key International, Inc. engages in the provision of an identity and access management platform. The firm's products include PortalGuard, Admin Panel, Hardware, Identity-Bound Biometrics, and MobileAuth. It offers its services to the education, finance, government, healthcare, manufacturing, and retail industries. The company was founded on January 7, 1993 and is headquartered in Holmdel, NJ.

BKYI At a Glance

BIO-key International, Inc.
101 Crawfords Corner Road
Holmdel, New Jersey 07733
Phone 1-732-359-1100 Revenue 6.93M
Industry Information Technology Services Net Income -4,300,692.00
Sector Technology Services Employees 42
Fiscal Year-end 12 / 2025
View SEC Filings

BKYI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.508
Price to Book Ratio 1.684
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.376
Enterprise Value to Sales 0.702
Total Debt to Enterprise Value 0.366

BKYI Efficiency

Revenue/Employee 164,989.786
Income Per Employee -102,397.429
Receivables Turnover 8.745
Total Asset Turnover 1.055

BKYI Liquidity

Current Ratio 0.414
Quick Ratio 0.331
Cash Ratio 0.096

BKYI Profitability

Gross Margin 81.393
Operating Margin -57.883
Pretax Margin -62.395
Net Margin -62.063
Return on Assets -65.496
Return on Equity -177.876
Return on Total Capital -77.502
Return on Invested Capital -168.057

BKYI Capital Structure

Total Debt to Total Equity 47.113
Total Debt to Total Capital 32.025
Total Debt to Total Assets 20.627
Long-Term Debt to Equity 2.486
Long-Term Debt to Total Capital 1.69
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-key International - BKYI

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.11M 7.02M 7.75M 6.93M
Sales Growth
+80.29% +37.26% +10.46% -10.64%
Cost of Goods Sold (COGS) incl D&A
1.67M 2.44M 6.32M 1.29M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
514.07K 546.01K 590.14K 477.53K
Depreciation
287.87K 199.15K 235.59K 172.55K
Amortization of Intangibles
226.20K 346.87K 354.56K 304.98K
COGS Growth
+110.48% +45.83% +159.21% -79.61%
Gross Income
3.44M 4.58M 1.43M 5.64M
Gross Income Growth
+68.54% +33.10% -68.75% +294.06%
Gross Profit Margin
+67.29% +65.25% +18.46% +81.39%
2021 2022 2023 2024 5-year trend
SG&A Expense
8.38M 12.62M 10.26M 9.65M
Research & Development
2.36M 3.25M 2.39M 2.51M
Other SG&A
6.03M 9.36M 7.86M 7.14M
SGA Growth
+15.71% +50.50% -18.70% -5.91%
Other Operating Expense
- - - -
-
Unusual Expense
- 60.00K 3.43M (396.20K)
EBIT after Unusual Expense
(5.00M) (11.47M) (8.43M) (4.01M)
Non Operating Income/Expense
(45.92K) (452.59K) (7.47K) (12.89K)
Non-Operating Interest Income
4.07K 233 11.53K 110
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.00K 10.46K 218.27K 299.75K
Interest Expense Growth
-99.59% -41.88% +1,986.31% +37.33%
Gross Interest Expense
18.00K 10.46K 218.27K 299.75K
Interest Capitalized
- - - -
-
Pretax Income
(5.07M) (11.93M) (8.66M) (4.32M)
Pretax Income Growth
+47.64% -135.51% +27.45% +50.05%
Pretax Margin
-99.05% -169.94% -111.62% -62.39%
Income Tax
- (20.43K) (134.01K) (23.00K)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - 40.99K
-
Income Tax - Deferred - Domestic
- - - (434)
-
Income Tax - Deferred - Foreign
- (20.00K) (175.00K) (23.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(5.07M) (11.91M) (8.52M) (4.30M)
Minority Interest Expense
- - - -
-
Net Income
(5.07M) (11.91M) (8.52M) (4.30M)
Net Income Growth
+47.64% -135.10% +28.45% +49.53%
Net Margin Growth
-99.05% -169.65% -109.89% -62.06%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(5.07M) (11.91M) (8.52M) (4.30M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(5.07M) (11.91M) (8.52M) (4.30M)
EPS (Basic)
-11.7027 -26.464 -15.21 -2.0878
EPS (Basic) Growth
+68.77% -126.14% +42.53% +86.27%
Basic Shares Outstanding
432.87K 450.04K 560.28K 2.06M
EPS (Diluted)
-11.7027 -26.464 -15.21 -2.0878
EPS (Diluted) Growth
+68.77% -126.14% +42.53% +86.27%
Diluted Shares Outstanding
432.87K 450.04K 560.28K 2.06M
EBITDA
(4.43M) (7.49M) (8.24M) (3.53M)
EBITDA Growth
+7.30% -69.17% -9.96% +57.10%
EBITDA Margin
-86.57% -106.70% -106.21% -50.99%

Snapshot

Average Recommendation BUY Average Target Price 2.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.15 Median PE on CY Estimate N/A
Year Ago Earnings -2.10 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Bio-key International - BKYI

Date Name Shares Transaction Value
Mar 24, 2025 Cameron E. Williams Director 11,787 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Robert J. Michel Director 13,406 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Manny Alia Director 12,426 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bio-Key International in the News